Table 1.
Patient characteristics
| Variable | Development set, n=161 | Validation set, n=147 | p-value | |
|---|---|---|---|---|
| Age | Mean | 62 | 68.8 | 0.098 |
| Range | 36–83 | 42–91 | ||
| Sex | Male | 26 (16.2) | 35 (23.8) | 0.115 |
| Female | 135 (83.8) | 112 (82.2) | ||
| Pre-treatment Hb | Mean | 13.1 | 13.2 | 0.339 |
| Range | 7.6–16.8 | 8.8–17.2 | ||
| T-stage | T1 | 14 (8.7) | 7 (4.7) | 0.067 |
| T2 | 90 (56.0) | 71 (48.4) | ||
| T3 | 40 (24.8) | 35 (23.8) | ||
| T4 | 15 (9.3) | 27 (18.4) | ||
| NA | 2 (1.2) | 7 (4.7) | ||
| N-stage | N0 | 91 (56.6) | 74 (50.3) | 0.012 |
| N1 | 26 (16.1) | 31 (21.1) | ||
| N2 | 34 (21.1) | 19 (12.9) | ||
| N3 | 10 (6.2) | 23 (15.7) | ||
| Global stage | I | 13 (8.1) | 9 (6.1) | 0.104 |
| II | 72 (44.7) | 47 (32) | ||
| IIIA | 29 (18.0) | 39 (26.5) | ||
| IIIB | 46 (28.6) | 45 (30.6) | ||
| NA | 1 (0.6) | 7 (4.8) | ||
| Grade | G1 | 12 (7.5) | 32 (21.8) | <0.01 |
| G2 | 86 (53.4) | 52(35.3) | ||
| G3 | 45 (27.9) | 33 (22.5) | ||
| NA | 18 (11.2) | 30 (20.4) |